Logo
x

Search

Subscribe Now

Neurocrine Biosciences

Neurocrine Biosciences Provides P-II (ERUDITE) Study Updates of Luvadaxistat for Cognitive Impairment Associated with Schizophrenia

Neurocrine Biosciences Provides P-II (ERUDITE) Study Updates of Luvadaxistat for Cognitive Impairment Associated with Schizophreni...

  • September 13, 2024
Neurocrine Biosciences Reports Positive Results from P-II study of NBI-1065845 in MDD

Neurocrine Biosciences Reports Positive Results from P-II study of NBI-1065845 in MDD

  • April 24, 2024
Neurocrine Biosciences Doses First Patient with NBI-1070770 in P-II Trial for Treating Major Depressive Disorder

Neurocrine Biosciences Doses First Patient with NBI-1070770 in P-II Trial for Treating Major Depressive Disorder

  • April 4, 2024
Neurocrine Biosciences Reports P-III (CAHtalyst) Pediatric Study Results of Crinecerfont in Children and Adolescents for Congenital Adrenal Hyperplasia

Neurocrine Biosciences Reports P-III (CAHtalyst) Pediatric Study Results of Crinecerfont in Children and Adolescents for Congenita...

  • October 6, 2023
Neurocrine Biosciences Reports P-III Study (CAHtalyst) Results of Crinecerfont for Congenital Adrenal Hyperplasia in Adults

Neurocrine Biosciences Reports P-III Study (CAHtalyst) Results of Crinecerfont for Congenital Adrenal Hyperplasia in Adults

  • September 13, 2023
PharmaShots Weekly Snapshots (August 21 – 25, 2023)

PharmaShots Weekly Snapshots (August 21 – 25, 2023)

  • August 25, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.